Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Addex Therapeutics Ltd
  6. News
  7. Summary
    ADXN   CH0029850754


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Addex Therapeutics to Release Q1 2021 Financial Results and Host Conference Call on May 5, 2021

05/03/2021 | 01:00am EDT

Geneva, Switzerland, May 3, 2021Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Q1 2021 financial results on Wednesday May 5, 2021. Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology will provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and the media on Wednesday, May 5, 2021 at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT).

Title:                Addex to Announce Q1 2021 Financial Results
Date:               May 5, 2021
Time:               16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT)

Joining the Conference Call:
1: In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.    
Dial-In Numbers:

  • Switzerland                +41 44 580 65 22
  • UK                                +44 20 30 09 24 70
  • U.S.A                        +1 87 74 23 08 30
  • Other Countries

2: Provide the Operator with the Participation Pin Code: 64754025#         

Link to live event online:
1: In the 10 minutes prior to the call start time, sign in online by following this Webex link.
2: Password: Welcome

About Addex Therapeutics:
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex’s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex’s lead product candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in Q2 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q2 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is scheduled to enter a phase 2a proof of concept clinical trial for the treatment of epilepsy in Q2 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC, which is focused on development for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange.

Press Contacts:

Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55        
Mike Sinclair
Partner, Halsin Partners
+44 (0)20 7318 2955
James Carbonara
Hayden IR
+1 (646)-755-7412

Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including in respect of the anticipated initiation and progress of clinical trials and preclinical studies, and its future financing activities. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in the Company’s Annual Report on Form 20-F filed with the SEC on March 11, 2021, as well as market conditions and regulatory review. 

Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements, except as required by law. 


Primary Logo

© GlobeNewswire 2021
06/17ADDEX THERAPEUTICS  : Shareholders Approve All Resolutions at Annual General Mee..
06/17PRESS RELEASE  : Addex Shareholders Approve All Resolutions at Annual General Me..
06/17Addex Shareholders Approve All Resolutions at Annual General Meeting
06/07ADDEX THERAPEUTICS  : Commences Enrollment in Phase 2 Trial of Epilepsy Drug
06/07ADDEX THERAPEUTICS  : First patients enrolled into multi-center U.S. study (Form..
06/07ADDEX THERAPEUTICS  : Enrolls First Patient in Mid-Stage Study of Epilepsy Drug
06/07PRESS RELEASE : Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
06/07Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
05/24PRESS RELEASE : Addex to Participate at the Benchmark Company Healthcare House C..
05/24ADDEX THERAPEUTICS  : to Participate at the Benchmark Company Healthcare House C..
More news
Sales 2021 1,61 M 1,74 M 1,74 M
Net income 2021 -15,1 M -16,3 M -16,3 M
Net Debt 2021 5,28 M 5,72 M 5,72 M
P/E ratio 2021 -3,63x
Yield 2021 -
Capitalization 68,0 M 73,7 M 73,6 M
EV / Sales 2021 45,5x
EV / Sales 2022 75,2x
Nbr of Employees 27
Free-Float 77,2%
Duration : Period :
Addex Therapeutics Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADDEX THERAPEUTICS LTD
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 1,08 CHF
Last Close Price 1,56 CHF
Spread / Highest target -30,8%
Spread / Average Target -30,8%
Spread / Lowest Target -30,8%
EPS Revisions
Managers and Directors
Timothy Dyer Chief Executive Officer & Director
Lénaic Teyssédou Head-Finance
Vincent M. Lawton Chairman
Roger G. Mills Director & Chief Medical Officer
Raymond George Hill Director
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.90.67%79 980
LONZA GROUP LTD14.63%52 508
CELLTRION, INC.-24.79%32 465
SEAGEN INC.-10.75%28 367